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Background: Current guidelines for the conduct of cost-effectiveness analysis (CEA) are mainly applicable to
facility-based interventions in high-income settings. Differences in the unit of analysis and the high cost of
data collection can make these guidelines challenging to follow within public health trials in low- and middle-
income settings.
Objective: This paper reflects on the challenges experienced within our own work and proposes solutions that
may be useful to others attempting to collect, analyse, and compare cost data between public health research
sites in low- and middle- income countries.
Design: We describe the generally accepted methods (norms) for collecting and analysing cost data in a single-
site trial from the provider perspective. We then describe our own experience applying these methods within
eight comparable cluster randomised, controlled, trials. We describe the strategies used to maximise
adherence to the norm, highlight ways in which we deviated from the norm, and reflect on the learning and
limitations that resulted.
Results: When the expenses incurred by a number of small research sites are used to estimate the cost-
effectiveness of delivering an intervention on a national scale, then deciding which expenses constitute ‘start-
up’ costs will be a nontrivial decision that may differ among sites. Similarly, the decision to include or exclude
research or monitoring and evaluation costs can have a significant impact on the findings. We separated out
research costs and argued that monitoring and evaluation costs should be reported as part of the total trial
cost. The human resource constraints that we experienced are also likely to be common to other trials. As we
did not have an economist in each site, we collaborated with key personnel at each site who were trained to use
a standardised cost collection tool. This approach both accommodated our resource constraints and served as
a knowledge sharing and capacity building process within the research teams.
Conclusions: Given the practical reality of conducting randomised, controlled trials of public health
interventions in low- and middle- income countries, it is not always possible to adhere to prescribed guidelines
for the analysis of cost effectiveness. Compromises are frequently required as researchers seek a pragmatic
balance between rigor and feasibility. There is no single solution to this tension but researchers are
encouraged to be mindful of the limitations that accompany compromise, whilst being reassured that
meaningful analyses can still be conducted with the resulting data.
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R
andomised, controlled trials of public health inter-
ventions are often conducted in more than one
context to gauge their effectiveness in different
populations (1, 2). The trials frequently need to establish
whether the interventions are cost-effective and econom-
ically feasible at scale (3). Current guidelines for the
conduct of cost-effectiveness analysis (CEA) are mainly
applicable to facility-based interventions in high-income
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settings, where the unit of randomisation is the indi-
vidual and patient level data is readily available (4, 5).
These guidelines can be difficult to implement for com-
plex interventions in resource poor countries, when pro-
vider cost data are unavailable or of poor quality and the
unit of randomisation is the cluster or village. Others have
begun to address the difficulties in adapting these guide-
lines to the low- and middle-income countries’ contexts
(6). To our knowledge, however, no study has yet con-
sidered the additional complexity of adapting those guide-
lines to compare findings among resource poor settings.
This paper thus aims to enrich the existing literature
on adapting guidelines for implementation in resource
poor settings. In addition, this paper aims to extend that
evidence base to highlight the challenges one might ex-
perience when it is necessary to compare findings from
trials conducted in different settings.
This paper reflects our own experience working within
community-based, cluster-randomised, controlled trials
conducted in seven sites, across four low- and middle-
income countries, between 1999 and 2011. We describe
the challenges of the costing process, the solutions and
strategies adopted, and the lessons learned. The inter-
vention we use as our working example involved women’s
groups practising participatory learning and action to
improve care-seeking and care practices. A meta-analysis
demonstrated that women’s groups are associated with a
34% reduction in maternal mortality and a 23% reduction
in neonatal mortality (7). This paper focuses only on the
process of cost data collection and analysis for these
trials and does not discuss the collection and analysis of
epidemiological data or cost-effectiveness.
This paper is organised as follows: We first provide
a detailed summary of the working example. We then
summarise available guidelines for identifying, collecting,
and analysing costs, before explaining our difficulties in
applying the guidelines. In that explanation, we highlight
the particular challenges that may arise when costs must
be compared among sites. Finally, we reflect on the key
lessons learned, emphasising those that may be general to
other studies of this type. Each section begins with a brief
review of the literature, followed by reflections on our
working example, highlighting the challenges encoun-
tered and describing the solutions adopted.
A working example: multisite community
participatory intervention
This paper draws on experience from eight cluster-
randomised controlled trials that tested the impact of
women’s groups on mortality. The groups had a four-
phase participatory learning and action cycle to identify
and prioritise problems during pregnancy, delivery, and
postpartum; to plan and implement locally feasible strat-
egies to address problems; and to evaluate their activities
(7). The unit of randomisation was the village (or slum-
cluster in Mumbai). The intervention employed local
facilitators (were not health workers) to conduct monthly
or fortnightly meetings. The first trial began in 2001 in
Makwanpur, Nepal, and seven similar trials were in-
itiated in other sites between 2005 and 2008. Four of the
sites adopted a factorial design and tested a second
intervention alongside the women’s groups (Table 1).
Context-specific health service strengthening was under-
taken to a varying degree in the intervention and control
areas in all trials. Further details of the trials and their
effectiveness have been published elsewhere (815).
Despite similarities in design and implementation,
there were differences among sites. These differences in-
cluded the size of the study population, the geography of
the study area, baseline neonatal and maternal mortality
rates, and participation rates among pregnant women.
There were also differences in the characteristics of the
implementing organisations, some of which were pre-
viously well-established, while others were set up for
the purpose of the trial. Such differences can challenge
standard guidelines for the collection and analysis of data
for a comparative costing. How then can research teams
allow for some acceptable level of heterogeneity while
Table 1. Women’s group trials
Location Organisation Trial dates (Baseline dates) Second intervention Cost analysis
Makwanpur, Nepal MIRA 20012003 (19992000) N/A Borghi et al. 2005
Dhanusha, Nepal MIRA 20072011 (20062007) Sepsis management Under progress
Orissa and Jharkhand, India Ekjut 20052008 (20042005) N/A Tripathy et al. 2010
Mumbai, India SNEHA 20062009 (20052006) N/A N/A (see More 2012)
Bangladesh BADAS-PCP 20052007 (2003) Resuscitation training N/A (see Azad et al. 2010)
Bangladesh (scale-up) BADAS-PCP 20092011 (2008) N/A Under progress
Malawi MaiKhanda 20082010 (20072008) Quality improvement Under progress
Mchinji, Malawi MaiMwana 20052009 (2005) Volunteer peer counselling Lewycka et al. 2012
Sources: Manandhar et al. 2004; Borghi et al. 2005; Tripathy et al. 2010; Azad et al. 2010; Houweling et al. 2011; More et al. 2012;
Colbourn et al. 2012; Prost et al. 2013.
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maintaining robust comparability across trials? This was
the task facing our research team in the context of
these trials.
General considerations for cost data
collection
Deciding how costs will be collected necessitates a number
of early decisions. Crucial decisions include study perspec-
tive, time horizon, how andwhere datawill be sourced, how
resource use will be measured and valued, and how
accounting costs will be adjusted to arrive at economic
costs. Finally, investigators need to consider how to allo-
cate joint costs, how to separate start-up costs from imple-
mentation costs, and whether to cost out other trial
activities such as monitoring and evaluating research, or
cost only the intervention itself. Each of these decisions
should be framed within the overall objectives of the study.
Our experience with this process is described here.
Perspective: patient, provider, or societal
A costing can be conducted from the perspective of the
patient, provider, purchaser, sponsor, government, or
society. Each of these perspectives will bear different
costs for the same intervention (16, 17). For example, if a
costing is conducted from the provider perspective, costs
incurred by patients would not be relevant.
In the context of our trials, two perspectives were
appropriate: provider and societal. The provider perspec-
tive enables any future provider to weigh the costs and
benefits (to their institution) of taking on this intervention
against those of other interventions. The societal perspec-
tive adds the costs of participation incurred by house-
holds to the costs incurred by the provider (3). Because
community participatory interventions may produce non-
health benefits such as community empowerment (15, 18),
a societal perspective would potentially capture health
and non-health costs and benefits to the women and their
communities, as well as to providers (3, 19).
For several reasons, we elected to adopt a provider per-
spective. In practice, our trial sites did not have sufficient
funds or field experience to collect the household level
economic data required for a societal perspective. In
addition, the monitoring and evaluation questionnaires
were already lengthy, and there was an ethical concern
about burdening respondents further. In Dhanusha,
Nepal, field teams complained that the monitoring and
evaluation questionnaire used in 2010 took a minimum of
two hours and two to three visits to complete. In this
situation, we might have conducted a separate ‘econom-
ics’ survey among a subset of households. However, our
surveillance teams were already fully committed, and we
could not afford to hire and train new teams. Further, we
were reluctant to subject participating households to yet
another data collection effort, fearing that this would
increase the likelihood of women dropping out of the trial
or refusing to participate in future work.
Time horizon
Interventions are typically evaluated for a period of ‘full
scale activity’ to assess the desired effects (20). The World
Health Organization recommends a 10-year time horizon
to explore the effectiveness of a trial in a single site, and
Ramsey et al. (21) recommend that a common time
horizon be used for costs and effects. Dhaliwal et al. (6)
however, argue that educational programmes can be
examined over a one- or two-year time frame because,
in this sector, start-up costs are relatively small. These
recommendations do not provide specific guidance for
costing community-based health interventions in multiple
sites.
In our case, and consistent with the approach sug-
gested by Ramsey et al. (21) the costing time horizon was
determined by the trial duration, that is, two-and-a-
half to three years. To this, we added a start-up period
that included activities conducted before the trial began.
The end point was the same as that used for calculating
programme effect, which was chosen by the team con-
ducting the epidemiological analysis.
Identifying, measuring, and valuing relevant costs
The literature suggests that cost collection methods de-
pend on the perspective of the CEA. In general, micro-
costing tends to be used for studies with a consumer or
societal perspective (22, 23), while gross-costing can be
used for a provider perspective (24).
Micro-costing records resource use at the patient (cost-
object) level and enumerates overheads and capital costs
such as office rent and electricity costs separately. These
costs are added to measure overall resource use and
the total cost of service provision (25, 26). Studies using
the micro-costing approach generally source data from
administrative databases, self-reported activity logs, time
and motion studies, and manager surveys (2527).
When gross-costing, the total cost of service provision
is first calculated at the institutional level and then
disaggregated to departments, service units, or patients.
Resources are generally assumed to be evenly distributed
across end users. For this reason gross-costing is not
suitable for services that are not the same for all end users
(25, 26, 28). Studies using a gross-costing approach fre-
quently collect retrospective data from accounting data-
bases, tariff books, market prices, or published studies.
Because these data are financial or accounting costs, they
need to be converted into economic costs. Economic
costs include the value of the next best alternative forgone
by making a particular choice. In practice, in our sites,
this meant that although donated goods and volunteer
time appeared as a zero cost in the accounting data, they
could not be treated as zero cost items for the purpose
of the economic costing. Treating such items as zero
CEA of complex interventions across multiple countries
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cost would result in a downward bias in the cost of the
intervention and an upward bias in the cost-effectiveness
ratio. This bias is particularly concerning if the goods are
not available for free in all settings or if the intervention
cannot be delivered using volunteers at scale or in all
settings (29). There is no consensus in the literature on
the ‘best’ technique for converting accounting costs to
economic costs, especially in resource poor settings. One
method is to use market prices (28). However, in such
settings, market prices may not reflect the true availability
of labour and capital owing to the presence of formal and
informal labour and capital markets. Market prices may
therefore need to be adjusted. A commonly used adjust-
ment technique is shadow pricing, wherein a good or
service is assigned a price defined by what an individual
must give up to gain an extra unit of the good or service
(29, 30). However, such adjustment techniques require
context and resource specific calculations, which are time
and labour intensive.
We took a provider perspective and collected costs
retrospectively using a gross-costing approach (9, 11, 31,
32). Data was sourced from project accounts of the partner
institutions in the study countries. Almost every site had
either made use of donated goods or volunteers to imple-
ment the intervention to some degree. For example, office
space in Dhaka, Bangladesh, was provided for free by the
government. This space was valued at private sector rental
rates. External consultants, who were not paid by the
project, provided key input into the start-up phase. For
these consultants, we estimated the number of consultancy
hours provided and valued this at a rate commensurate
with their qualifications and work experience.
In addition to the expected challenges of converting
accounting to economic costs, we encountered another
practical limitation of project accounts data not com-
monly documented in the literature. In Bangladesh, we had
more than one funder over the full duration of the trial, and
each funder kept project accounts using their own method
within their own files. Calculating costs for this trial
required sourcing cost data from multiple sources includ-
ing funders no longer involved with the trial. These data
then had to be reconciled (i.e. significantly reformatted)
before they could be combined. Some of the data was
available in hard copy form only and needed to be entered
into a spread sheet before we could begin the process of
reconciliation. This process was significantly more com-
plex and time consuming than we had anticipated and
resulted in delays to the final analysis of cost-effectiveness
and to the publication of the main trial paper (10).
Dealing with joint costs
Joint costs occur when two or more outputs, services,
or activities are produced from the same input. Common
examples include staff who work in both research
and implementation or who oversee several arms of a
multi-arm trial. The same could be said for office space
housing staff from different projects or having different
functions within a single project. If a resource is used by
several components of an intervention, or by other
programmes that are not part of the intervention, the
cost associated with that resource must be allocated
proportionally in some way. This is commonly done by
assessing time or resource use, measured either by ob-
servation or by self-reported methods (17).
For each of our research sites, we needed to distinguish
start-up from running costs, women’s groups from health
service strengthening, our package of interventions from
other intervention(s) implemented by partner institutions,
monitoring and evaluation from implementation, research
from implementation, and process evaluation from im-
plementation. At all sites, we could directly assign most
incurred costs to these categories using appropriate labels
in the project accounts. However, for resources that were
used across categories, we had little prospective informa-
tion to use as a basis for the proportional allocation of
costs. In some cases, we used information from vehicle
logbooks to allocate vehicle purchase, maintenance, and
fuel costs as well as drivers’ salary costs (MaiMwana trial)
or used fax machine minutes for fax machine costs
(Bangladesh trial). Staff time sheets for managerial or
administrative staff were available for only two of the trials
(Makwanpur and Ekjut trials) (8, 9).
We allocated programme costs to components or
categories using a two-step process. First, we directly
allocated as many of the staff, material, and capital cost
items as possible using the methods described above.
Second, the economics team, in consultation with local
managerial staff, decided upon a joint cost allocation rule
to divide the remainder among the programme compo-
nents. For example, in MaiMwana (Malawi), 25% of
the joint costs were allocated to women’s groups, 25%
to monitoring and evaluation, 19% to the peer counsel-
ling intervention, 16% to health service strengthening,
10% to process evaluation, and 5% to research. In the
Bangladesh scale-up trial, 40% was allocated to women’s
groups, 40% to monitoring and evaluation, and 10%
to health service strengthening and process evaluation,
respectively. Although this resulted in differing alloca-
tion rules across sites, the decisions reflected the under-
standing of actual resource use by local staff who had
worked in the implementing organisation during the trial.
Start-up and implementation costs
Separating start-up and implementation costs is essential
if the analysis must tabulate the cost of scaling up
an intervention. If, however, an intervention is tested at
scale, this may not be necessary. The start-up period is
the time between the decision to implement an interven-
tion and delivering it to the first beneficiary (33).
Typically, start-up costs include (but are not limited to)
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costs incurred when recruiting personnel, procuring
office space and equipment, and training field workers.
Implementation costs are those incurred when the inter-
vention is being implemented and commonly include
salaries, transportation costs, overheads, additional ma-
terials, and capital goods.
In Nepal (8), we defined start-up costs by type of
activity. For example, the design of the pictorial card game
was classified as a women’s group start-up cost, and the
design of health worker training manuals was classified as
a health service strengthening start-up cost (31). However,
the field team found this process time intensive and
onerous and were reluctant to further participate in the
costing. As such, we took a more pragmatic approach to
ensure the on-going cooperation of the field teams. We de-
fined a start-up period during which all costs incurred
were classified as start-up. The remainder of the costs were
classified as implementation costs. In a few instances,
costs incurred in the implementation period were classi-
fied as start-up if we considered them to be essential for
implementation to continue. These included the recruit-
ment and training of new facilitators to replace facilita-
tors who dropped out or moved away. Training of health
staff was part of the health service strengthening provided
to intervention and control areas and therefore was an
implementation cost.
Research and monitoring and evaluation costs
Once an intervention proves to be effective in a given
context, scaling up or replicating that intervention will
seldom require the same research activities required for the
initial trial. However, some on-going monitoring and
evaluation of the intervention is desirable. The economic
evaluation of a trial may want to split research from
implementation costs and monitoring and evaluation from
research costs. The study by Gilson et al. (34) is one of the
few to report that research costs were excluded from the
cost analysis. We were unable to find any study that
distinguished monitoring and evaluation costs from re-
search costs.
In our trials, we defined monitoring and evaluation as
all activities conducted by the surveillance team including
data officers who conducted data entry and cleaning. It
was relatively straightforward to identify the monitoring
and evaluation costs because all our sites had a separate
monitoring and evaluation team. Thus, all monitoring
and evaluation expenses were a separate line item in the
project accounts. We defined research costs as activities
related to the analysis of data, dissemination of results,
and planning of further interventions. Most research
activities were conducted by staff from the UK partner
institution. However at all sites, local staff also engaged
in research activities. Our task was to identify and deduct
the latter type of research cost from local project
accounts. We identified the cost of meetings and travel
for which the primary purpose was research, retro-
spectively estimated the proportion of time that indivi-
dual local staff members spent on research each year, and
used this proportion to allocate relevant capital costs
(e.g. laptops) to research. We also assigned a proportion,
based upon staff time use, of all joint costs to research.
These research costs were then deducted from the total
cost of the project, while the monitoring and evaluation
costs were included in the total cost.
Owing to the design of randomised controlled trials,
roughly half of monitoring activities are conducted in
control areas. It could be argued that this is a research
cost that should be subtracted from the total programme
cost. We encountered two main difficulties in doing so.
The first is that we only had one monitoring and
evaluation team per site and therefore, could not clearly
differentiate between the costs incurred in intervention
versus control areas. Second, the very act of monitoring
may have had an impact on the effectiveness of the
intervention. Thus, we did not attempt to identify the
proportion of monitoring and evaluation activity that
was a part of research activity. Instead, we calculated
total monitoring and evaluation cost and reported this
alongside the intervention implementation cost.
Complexities of a multisite CEA
Making cost collection decisions, as described earlier,
can be challenging in a single setting. Making those de-
cisions when the results must be comparable across
multiple settings can be complex in the extreme. In partic-
ular, we reflect upon our efforts at collaboration and
standardisation.
Collaborative efforts in cost identification and
collection
Many economic evaluations may be conducted by eco-
nomists based in the evaluating institution and not by
staff at trial sites, making a very strong case for collabora-
tion on the CEA of a multisite, randomised, controlled
trial. First, collaboration provides opportunities for skill
sharing and capacity building, enabling the integration
of economic activities into country teams (1). Second,
no one economist can be in all sites at all times, and few
funders will finance one qualified economist per site!
Third, collaboration facilitates data consistency.
We found it useful to establish a key ‘costing contact’
at each site to oversee data collection. This ensured that
costs were captured without creating a significant addi-
tional burden or without introducing parallel systems
that replicated data already being collected for other
purposes. These contacts were not all economists or
finance personnel but were those interested in the costing
process and volunteered to take on the role. Our costing
contacts collected data with the help of a custom-made
tool described in the next section. Although we found
CEA of complex interventions across multiple countries
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collaboration beneficial overall, we also argue that it was
important to have a central lead on the CEA who was
able to support the sites, ensure overall consistency, and,
ultimately, shape the final analysis.
Standardisation: designing a cost collection tool
Standardising economic evaluation methods enables
users to compare the results of evaluations for different
interventions or for a similar intervention in different
settings (35). The key ‘standard’ aspects that facilitate
comparative analysis are the perspective, measures of
outcome or effect, and the definition of inputs and costs
(35, 36). If the collection of costs is decentralised to
implementing partners who may have varying levels of
expertise with economic evaluation, achieving this level
of standardisation can be challenging.
During design and implementation of our trials,
economists were engaged on an ad hoc basis (9, 21).
This resulted in variable progress toward conducting
the costing activities across different sites, despite the
development and distribution of a manual describing the
processes used to collect and analyse the cost data of
the first trial (31). To facilitate a comparative costing
and to enhance standardisation across our trials, the UK
partner institution appointed an economics team in 2009
with overall responsibility for the evaluation of the trials.
This led to the design of a common costing tool to be
used for each site.
Because the software platform for the costing tool
needed to be universally accessible, we avoided the use of
specialised statistical and data management software. We
used a compatible version of MS Excel, already available
and extensively used by all partner institutions. The tool
was designed in a way to be easy for a non-economist to
understand and use. To ensure that this, the costing
contact and other key researchers at the trial site met for
a one-day workshop to discuss the purpose of the tool, to
learn how to use it, and to agree on definitions of relevant
cost categories. Following a first draft of the tool, the UK
economics team conducted a series of one-to-one training
sessions with key costing contacts at each site. These
sessions revealed the degree to which flexibility was
needed in the tool to incorporate previously described
differences in the structure of the trial, activities, and
priorities among the sites. Feedback, opinions, and con-
cerns regarding the use of the tool continue to be shared
between the key costing personnel in the UK and the trial
sites via e-mail and Skype.
The costing tool will be available in the public domain
when the trial data are released. Table 2 presents the
Table 2. Costing tool structure
Categories of costs Data input Examples of items
Main input categories:
Staff time and salaries Salaries and other staff costs. Annual
allocation (hours or percentage).
Salaries of programme staff; facilitators;
identifiers; volunteers.
Materials and equipment Purchase year and price.
Allocation.
Items that have no resale value after 1
year (e.g. picture cards, questionnaires,
HIV testing kits, raincoats).
Capital costs Purchase date, price, and expected useful
life (for items owned).
Annual recurrent costs.
Annual allocation.
Buildings, vehicles and equipment with
an expected useful life 1 year (e.g.
laptops, bicycles, cars, photocopiers,
office premises).
Joint costs Summarises share of staff, material, and
capital costs already allocated to joint costs.
Allows additional items to be input.
Audit fees, licence fees, fuel and travel
refunds, training and recruitment costs,
meeting costs.
Summary sheets and additional data entry by programme component:
Women’s group facilitation
Health service strengthening or
other intervention(s)
Monitoring and evaluation
Process evaluation
Research
Each sheet summarises the share of
allocated joint costs and directly allocated
staff, material, and capital costs. Additional
costs may also be entered.
Fuel and travel refunds, training and
recruitment costs, project material
development costs, meeting costs.
Results sheets:
National currency US dollars Detail of costs with various breakdowns.
Cost-effectiveness The user is able to input programme effect
data and calculate cost-effectiveness.
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structure of the tool. The main worksheets for entering
data are staff, material, capital, and joint costs. We also
created worksheets that summarise the costs (including
a share of joint costs) by programme components (e.g.
women’s groups) and that allow additional items to be
entered. The final worksheets present results and allow
effect data to be entered and cost-effectiveness results to
be calculated.
Discussion
Some of the challenges that we faced while collecting
and analysing the cost data across multiple sites may be
common to data collection processes for single and mul-
tiple site costings. For both, we offer practical solutions
for resource poor settings. We do not discuss analytical
methods in detail because the use of decision trees
or modelling techniques is more closely related to the
purpose of economic evaluation.
An important consideration in a costing is the accurate
identification and categorisation of different costs. In our
trials, this was the case with identifying start-up costs,
in particular. Early start-up activities were not always
separately identified or even included in project accounts.
This is likely to be an issue with all trials where there
are multiple funding sources and where interventions
are planned before funding begins. We recommend that
in such a scenario, the staff involved build a common
understanding of cost components and activities and
work to reconcile cost data from multiple sources that
may be duplicated in different databases or that are
available in different formats.
Another very important consideration is whether to
exclude research costs from analysis. Separating out the
research costs specific to a trial setting from intervention
implementation costs is informative if the results are used
to estimate scale-up or implementation costs in another
setting. We excluded research costs from our analysis
but included monitoring and evaluation costs. Although
research activities are distinctly necessary in a trial
setting, some degree of monitoring and evaluation is
desirable when interventions are rolled out. One solution
for distinguishing between the two is to identify a mini-
mum amount of cost for monitoring and evaluation and
to assign the remainder to research. Another is to identify
activities that are clearly research driven, such as control
area surveillance, and allocate costs for those activities
to research. In the absence of a good allocation method,
a conservative approach such as ours is advisable. We
simply reported all monitoring and evaluation costs as
part of the total project cost. In our trials, we could not
rule out the possibility that intense and visible surveil-
lance activities in the community have positive external-
ities or other unintended positive health outcomes.
Excluding monitoring and evaluation in this situation
would risk underestimating the total cost and over-
estimating the cost-effectiveness of the intervention.
To carry out a comparative CEA across multiple sites,
it is imperative to collect data that is consistent across all
sites. In our experience, collaboration with key costing
personnel at each site, led by the UK economics team,
proved to be very successful in identifying and collecting
provider cost data. The design and use of a custom cost
collection tool built on an accessible platform allowed
data to be collected in a consistent manner. The tool also
allowed a degree of flexibility in the data collection that
reflected important site-specific characteristics. The tool
and the manner in which it was used by the in-country
and UK partners allowed knowledge sharing and capa-
city building. Further, the collaborative process allowed
us to collect the data in a timely manner and to ensure
quality.
We found no consensus in the guidelines on how to
choose appropriate time horizons or discount rates for
costs, especially for community participatory trials in
low- and middle-income countries. We believe that the
choice of these would depend on the setting of the trial as
well as the expectations of scale-ups or replication.
Learning from our experience over a decade, we are
able to contribute toward the improvement of cost data
collection methodology and systems. This experience has
highlighted the importance of planning ahead and of
being prepared for the possibility of unexpected events.
For example, the start-up of the Dhanusha and Mchinji
trials was delayed because of a Maoist uprising and
because of unexpected personal events, respectively.
Guidelines or recommendations on whether and how to
factor in such events into analysis are non-existent. In our
case, the delays occurred before implementation. The
associated costs were therefore included as part of the
start-up costs, effectively becoming one of many factors
that contributed to differences in start-up costs across the
sites.
Finally, it is worth noting that, given the lifespan of
these trials, the staff involved in evaluating the costs and
benefits of the interventions has changed. We tried to
ensure consistency over time by exchanging information
with outgoing researchers, constructing a costing tool
that is standardised yet has sufficient flexibility to be
adapted by partners for subsequent use, and by training
groups of staff on the methods used. The truth is that,
with the movement of researchers into and from a pro-
ject, there will also be a movement of ideas. This presents
an opportunity to improve what has been done in the
past and poses a challenge to maintain consistency and
comparability over time. Trials conducted over multiple
sites tend to be large collaborations of implementing and
research partners. Each partner will bring their own ideas
about what is most important within the research process
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and how the objectives of the trial may best be achieved.
Many of the decisions made regarding a comparative
CEA will be made by these different teams. These deci-
sions are likely to reflect necessary compromise in the
design, implementation, and analysis.
Our reflections on the practical considerations of
collecting cost data for a comparative costing of multiple
sites is not an exhaustive list of guidelines or of the chal-
lenges faced. It outlines some of the main steps involved
in data collection for the economic evaluation of a single
site trial and describes our experience putting these steps
into practice across multiple sites. In doing so, we provide
pragmatic solutions to common problems that may be
faced when costing a cluster randomised, controlled, trial
in resource poor settings. Further, we hope that the dis-
cussion in this paper encourages researchers other than
economists to conduct economic evaluations of their
interventions.
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